Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 06, 2022 08:00 ET | Source: Brain Canada

Lancement de la toute première plateforme canadienne en santé mentale des jeunes, qui transformera la recherche et les traitements

MONTRÉAL, 06 oct. 2022 (GLOBE NEWSWIRE) -- Ce projet avant-gardiste pour la santé mentale des jeunes améliorera la compréhension générale des besoins en santé mentale des jeunes et fera...
October 06, 2022 08:00 ET | Source: Tempest Therapeutics

Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit

Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” SessionNicholas DeVito, M.D, Duke University School of Medicine, to present...
October 06, 2022 08:00 ET | Source: Aemetis, Inc.

Aemetis Biogas Closes $25 Million USDA Guaranteed Project Financing With Greater Commercial Lending for Dairy Farm Biogas Digesters and Pipeline to Produce Renewable Natural Gas

Project Processes Methane From California Dairy Farms Into Renewable Natural Gas for Use as Low-carbon Transportation Fuel CUPERTINO, CA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...
October 06, 2022 08:00 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Recent positive MELAS clinical study data drive urgency to deliver potential first-ever therapy for patients with rare, genetic mitochondrial diseases Development programs prioritized and...
October 06, 2022 08:00 ET | Source: Galectin Therapeutics Inc.

Galectin Therapeutics Reports the Positive Outcome of the Second Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

NORCROSS, Ga., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its...
October 06, 2022 08:00 ET | Source: Cabaletta Bio

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

PHILADELPHIA, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for...
October 06, 2022 08:00 ET | Source: Aruna Bio

Aruna Bio Announces Presentation on Neural Exosome Treatment Opportunities and Lead Program, AB126 at Exosome Based Therapeutic Development Summit

-AB126 is an unmodified exosome derived from neural stem cell lines with the innate ability to cross the blood-brain-barrier- -Preclinical data demonstrate the potential therapeutic activity of AB126...
October 06, 2022 08:00 ET | Source: Fintech

S&G Stores Implements Fintech’s Alcohol Invoice Payment Solution Across All Locations

TAMPA, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Financial Information Technologies, LLC (“Fintech”), the leading B2B solutions provider for the beverage alcohol industry, has been selected as the...
October 06, 2022 08:00 ET | Source: Nine Mile Metals Ltd.

Nine Mile Metals UAV Drone Survey Discovers (3) Massive VMS Source Targets and (2) New Spruce Lake Formation Target Systems

VANCOUVER, British Columbia, Oct. 06, 2022 (GLOBE NEWSWIRE) -- NINE MILE METALS LTD. (CSE: NINE, OTCQB: VMSXF, FSE: KQ9) (the “Company” or “Nine Mile”) announces its 1,000-line Kms UAV Magnetics...
October 06, 2022 08:00 ET | Source: Celularity, Inc.

Celularity Promotes Two Executives in Executive Leadership Team

FLORHAM PARK, N.J., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placenta-derived allogeneic cell therapies,...

1 ...78293 78294 78295 ...326067